Amarin's REDUCE-IT Legacy Data Suggests Durable Cardiovascular Benefits Post-Treatment
Event summary
- Amarin presented new REDUCE-IT Legacy analysis at ESC Congress 2026, showing persistent cardiovascular benefits in adherent patients post-icosapent ethyl (IPE) treatment cessation.
- Highly adherent patients (on IPE for ≥1.5 years) experienced ~30% relative risk reduction in major adverse cardiovascular events.
- Secondary prevention patients who stopped IPE after 2.3 years maintained a hazard ratio of 0.73 for up to four years post-discontinuation.
- REDUCE-IT trial followed 8,179 patients across 11 countries, with primary results published in 2018.
The big picture
Amarin's data reinforces the growing recognition of 'legacy effects' in cardiovascular medicine, where sustained treatment can alter disease trajectories long after therapy ends. This aligns with broader trends in preventive cardiology emphasizing long-term adherence and durable benefits. The findings could strengthen VASCEPA/VAZKEPA's position in a market increasingly focused on reducing residual cardiovascular risk beyond statin therapy.
What we're watching
- Treatment Adherence
- How Amarin will leverage these findings to improve patient adherence and long-term outcomes.
- Market Differentiation
- Whether the legacy effect data will further differentiate VASCEPA/VAZKEPA in the competitive cardiovascular market.
- Regulatory Strategy
- The pace at which Amarin advances regulatory discussions for expanded indications based on these durability insights.
Related topics